Compare Mesoblast Limited (MESO) vs Norwegian Cruise Line Holdings Ltd (NCLH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs Norwegian Cruise Line Holdings Ltd — how do they compare? Mesoblast Limited trades at $14.29 (market cap $1.75B), while Norwegian Cruise Line Holdings Ltd trades at $15.57 (market cap $7.11B). The key difference: Norwegian Cruise Line Holdings Ltd is far larger — about 4.1× Mesoblast Limited's market cap, and Mesoblast Limited is more actively traded (239,027 versus 22,683,268). Which is the better fit depends on your goals — on Pluang, investors hold Mesoblast Limited for 15 Days and Norwegian Cruise Line Holdings Ltd for 68 Days on average.
| MESO | NCLH | |
|---|---|---|
Market Cap | $1.75B | $7.11B |
Volume | 239,027 | 22,683,268 |
Sector | Health | Consumer Cyclical |
52-Week High | $20.96 | $25.02 |
52-Week Low | $13.19 | $14.12 |
Typical Hold Time | 15 Days | 68 Days |
Enterprise Value | $1.83B | $21.93B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $13.75, down 1.36% on the day, with a bearish technical signal from moving averages. The company reported a net loss of $102.14 million in 2025, though revenue grew to $120 million in 2026. Recent milestones include FDA approval for a new potency assay and completion of a Phase 3 trial for chronic low back pain, signaling progress in its commercial pipeline.
The outlook is mixed; analyst consensus leans buy (45% buy ratings), but profitability remains a challenge with negative margins. Key risks include high cash burn and competitive pressures, while catalysts hinge on successful commercialization of RYONCIL and upcoming trial results. The stock presents a high-risk, high-reward opportunity in the biotech sector.
Norwegian Cruise Line Holdings (NCLH) trades at $15.49, up 2.92% on the day, with a bullish technical signal and recent earnings beats driving momentum. The company shows strong profitability with a 7.49% net income margin and attractive valuation metrics, including a P/E of 9.39. Recent news highlights management's focus on booking strategies and debt management, with a $950 million senior notes offering priced in September 2026. Analyst consensus is positive, with a $20.86 price target implying significant upside from current levels.
The outlook for NCLH is cautiously optimistic, supported by earnings strength and analyst buy ratings, but risks include high debt levels and yield pressure. Investment opportunity lies in valuation discount and operational improvements, though investors must monitor competitive dynamics and macroeconomic sensitivity. The stock's trajectory hinges on sustained demand and effective capital allocation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About Norwegian Cruise Line Holdings Ltd
Norwegian Cruise Line is the world's third-largest cruise company by berths (at more than 62,000), operating 29 ships across three brands (Norwegian, Oceania, and Regent Seven Seas), offering both freestyle and luxury cruising. The company has redeployed its entire fleet as of May 2022. With eight passenger vessels on order among its brands through 2027 (representing 20,000 incremental berths), Norwegian is increasing capacity faster than its peers, expanding its brand globally. Norwegian sailed to around 500 global destinations before the pandemic.
Read more on NCLH →
